LeMaitre Vascular's (LMAT) steady average selling price increases for its products raised questions over its sustainability, Oppenheimer said in a Friday note.
"Continually switching to direct selling platforms helps in
tolerating ASP increases and allows for higher GM on products, though unclear how sustainable the consistent pricing increases are in the longer-term," Oppenheimer analysts said.
In addition to the sustainability issue, they also pointed to the premium valuation of the shares and potential tariff impact.
Oppenheimer downgraded the stock to perform from outperform and removed its $93 price target, saying that it is "moving to the sidelines as PT achieved."
LeMaitre shares were down more than 7% in recent trading.
Price: 92.74, Change: -7.17, Percent Change: -7.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.